STRO - SUTRO BIOPHARMA, INC.
34.58
3.030 8.762%
Share volume: 201,817
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$31.55
3.03
0.10%
Fundamental analysis
10%
Profitability
0%
Dept financing
12%
Liquidity
37%
Performance
13%
Performance
5 Days
17.82%
1 Month
62.12%
3 Months
118.86%
6 Months
2,781.67%
1 Year
6,161.09%
2 Year
817.24%
Key data
Stock price
$34.58
DAY RANGE
$31.55 - $34.58
52 WEEK RANGE
$0.67 - $34.58
52 WEEK CHANGE
$4,670.97
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.
Recent news